9999999997-18-007412.txt : 20180822 9999999997-18-007412.hdr.sgml : 20180822 20180822134100 ACCESSION NUMBER: 9999999997-18-007412 CONFORMED SUBMISSION TYPE: CT ORDER PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20180822 DATE AS OF CHANGE: 20180822 ACTION DATE: 20180822 RECEIVED DATE: 20180822 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Kala Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001479419 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 270604595 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CT ORDER SEC ACT: 1934 Act SEC FILE NUMBER: 001-38150 FILM NUMBER: 181032130 BUSINESS ADDRESS: STREET 1: 100 BEAVER STREET STREET 2: SUITE 201 CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 781-996-5252 MAIL ADDRESS: STREET 1: 100 BEAVER STREET STREET 2: SUITE 201 CITY: WALTHAM STATE: MA ZIP: 02453 CT ORDER 1 filename1.pdf begin 644 filename1.pdf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